IRIDEX (IRIX) Investor presentation summary

Strategic vision and mission

• Aims to transform laser-based eye care to preserve sight and improve quality of life for patients with ophthalmic conditions globally.

• Focuses on delivering innovative, clinically proven, non-invasive laser technologies for glaucoma and retinal disorders.

Product portfolio and technology

• Offers established laser systems and delivery devices for retina and glaucoma treatments, including IQ 532®, IQ 577®, PASCAL®, Cyclo G6®, MicroPulse P3®, and G-Probe®.

• MicroPulse® technology minimizes tissue damage by allowing tissue cooling between laser pulses.

• EndoProbe® handpieces generate 22% of retina business with recurring revenue.

Market opportunity and commercial footprint

• Global retina laser market projected at $250.4M in 2026, with 8.6M treatments and 3.2% CAGR.

• U.S. glaucoma probe market opportunity estimated at $500M; rest of world at $700M.

• Commercial presence in over 100 countries, with direct and distributor sales teams.